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Abstract
Cervical cancer is one of the leading causes of death in 
women worldwide, particularly in developing countries. 
Human papillomavirus has been reported as one of the 
key etiologic factors in cervical carcinoma. Likewise, 
epigenetic aberrations have ability to regulate cancer 
pathogenesis and progression. Recent research su-
ggested that methylation has been detected already at 
precancerous stages, which methylation markers may 
have significant value in cervical cancer screening. The 
retinoic acid receptor beta (RARβ ) gene, a potential 
tumor suppressor gene, is usually expressed in normal 
epithelial tissue. Methylation of CpG islands in the 
promoter region of the RARβ  gene has been found to 
be associated with the development of cervical cancer. 
To investigate whether RARβ  methylation is a potential 
biomarker that predicts the progression of invasive 
cancer, we reviewed 14 previously published articles 
related to RARβ  methylation. The majority of them 
demonstrated that the frequency of RARβ  promoter 
methylation was significantly correlated with the se-
verity of cervical epithelium abnormalities. However, 
methylation of a single gene may not represent the 
best approach for predicting disease prognosis. Ana-
lyzing combinations of aberrant methylation of multiple 
genes may increase the sensitivity, and thus this app-
roach may serve as a better tool for predicting disease 
prognosis.
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Core tip: The frequency of retinoic acid receptor beta 
promoter methylation was significantly correlated with the 
severity of cervical epithelium abnormalities. However, 
a single gene may not represent the best approach for 
predicting disease prognosis. Thus, combinations of 
aberrant methylation of multiple genes may as a better 
tool for predicting disease.
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INTRODUCTION
Cervical cancer is the leading cause of death in women 
worldwide. The prevalence is high in women in low- 
to middle-income countries[1]. In 2012, approximately 
522000 women globally were diagnosed with cervical 
cancer, and the mortality rate due to cervical cancer 
was reported to be 266,000 cases/year[2]. The highest 
incidence occurred in sub-Saharan Africa while in Asia, 
cervical cancer remains the third most common cancer 
(after breast and lung cancer), with an estimated 
285000 new cases and 144000 deaths in 2012[3]. The 
age-standardized incidence rates (ASRs) of cervical 
cancer estimated by GLOBOSCAN in 2012 indicated 
that the ASR is higher in less developed compared to 
more developed regions[4]. In Thailand, the age group 
with the highest incidence is 45-70 years[5].
Several studies had found that cervical cancer is 
preceded by a pre-invasive stage, in which abnormal 
cells are confined to the cervical epithelium. The pre-
invasive stage is also known as cervical intraepithelial 
neoplasia (CIN). The 2014 Bethesda System categorizes 
squamous epithelial cell abnormalities as atypical 
squamous cell of undetermined significance (AS-CUS); 
low-grade squamous intraepithelial lesion (LSIL), which 
was previously known as CIN Ⅰ; high-grade squamous 
intraepithelial lesion (HSIL), which was previously 
known as CIN Ⅱ and Ⅲ; or squamous cell carcinoma 
(SCC)[6]. SCC represents > 80% of cervical cancers, 
while adenocarcinoma (AC) accounts for the rest.
The standard method for screening for early-stage 
cervical neoplasia is cytological morphologic assessment 
of cervical scrapings. The sensitivity of the conventional 
Pap smear for identifying CIN Ⅱ+ is 55.2%, while the 
sensitivity of liquid-based cytology is 57.1%[7]. High-
risk human papillomavirus (HPV) DNA testing in 
combination with the conventional Pap smear increases 
the sensitivity. Furthermore, biomarkers of oncogenic 
progression would improve the accuracy of cancer 
progression predictions. Epigenetic biomarkers may 
help to fulfil this role, and they have the additional 
benefit predicting the stage of cervical carcinogenesis 
progression[8].
GENOME OF HPV
HPV is a small, non-enveloped and circular double-
stranded DNA virus with a genome of approximately 8 
kb in length[9]. The HPV genome comprises eight protein-
coding genes and a noncoding region that is referred to 
as the regulatory long control region[10]. Only one strand 
of the DNA carries the protein-coding sequence[11]. 
Regarding the protein-coding genes, the genes are 
designated as early (E) or late (L) to indicate when 
the proteins are expressed in the viral life cycle[12]. The 
eight protein-coding gene consist of E1, E2, E4, E5, 
E6, E7, L1 and L2[9]. E1 and E2 are highly conserved 
and involved in viral DNA replication[13-15]. L1 and L2, 
which both have a high degree of sequence variation, 
encode for viral packaging proteins[16]. E4 releases the 
viral particle from the epithelial cells[17]. E6 and E7 are 
viral oncogenes that are involved in the integration of 
the HPV genome into the host genome[18]. There are 
more than 130 genotypes of HPV, which are categorized 
based on sequence variation in their L1 region[19]. Of the 
130 genotypes, at least 40 genotypes infect the genital 
areas of humans via sexual transmission. HPV can 
also be classified into cutaneous or mucosal types[12]. 
The mucosal type can be subdivided into high-, 
intermediate-, or low-risk types[20]. 
HPV AND CERVICAL CANCER
The most important risk factor for cervical cancer 
is HPV infection, which has been found in 90.7% of 
cervical cancer patients worldwide[21]. HPV infection is 
a sexually transmitted disease. It has been estimated 
that more than 80% of sexually active women become 
infected with HPV, while more than 50% of young 
women become infected after they first have sexual 
intercourse[22]. The oncogenic potential of HPV depends 
on the genotype. HPV 16 and 18 are the most common 
types associated with invasive cervical cancer[23]. Other 
HPV genotypes have been found to be related to cancer, 
but their oncogenic risk differs among the various 
populations, geographic regions, and age groups. 
At the country level, collecting baseline data on 
the local burden of specific HPV genotypes related to 
cervical cancer is important. This information can impact 
the local HPV vaccination policies. A meta-analysis 
revealed that HPV 16, 18, 31, 33, 45, 52, and 58 are 
responsible for more than 90% of cervical cancers 
worldwide[20]. These genotypes represent the baseline 
genotypes to include in a vaccine targeting the genotypes 
circulating in the population[4]. The current HPV vaccines 
were developed to prevent HPV infection, and thus 
prevent cervical carcinoma. HPV vaccines have been 
implemented in routine vaccination programs in several 
developed and developing countries worldwide[24]. To 
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date, there have been three HPV vaccines in clinical use: 
Bivalent, quadrivalent, and nanovalent vaccines[25]. 
Other independent risk factors such as immuno-
suppression, individual lifestyle, and smoking have been 
found to be associated with the development of HPV-
related cervical cancer[21,26]. Most HPV infection is transient, 
and clearance of the virus can occur spontaneously over 
a 3-year period[27]. However, in some cases, persistent 
infection can result in cervical cancer development. The 
transition from dysplasia to invasive carcinoma may take 
several years to decades to develop. HPV initially infects 
the basal layers of the epithelium through micro-wounds. 
The virus begins to replicate, and when infected daughter 
cells migrate to the upper layers of the epithelium, the 
viral late genes are activated, and viral DNA is packaged 
into capsids. Progeny virions are released to re-initiate 
infection, which can result in persistent and/or asymp-
tomatic infection[28]. The integration of HPV into the host 
genome can lead to carcinogenic transformation. Certain 
regions of the human genome are favored for viral DNA 
insertion such as fragile sites, rupture points, translocation 
points, and transcriptionally active regions[29]. Moreover, 
the virus can induce epigenetic modification of viral and 
cellular genes, which affect their expression, leading to 
malignant cell transformation[30,31].
HOST GENETIC FACTORS AND 
CERVICAL CANCER
Diverse immunogenetic associations with HPV infection, 
persistence, and transformation have been extensively 
investigated. Recent studies have looked at multiple 
genes in various populations with different environment 
interactions[32]. HPV infection alone might not be 
sufficient for the development of cervical carcinoma, and 
certain antigen-processing machinery (APM) and single-
nucleotide polymorphisms (SNPs) may lead to a smaller 
immunogenic peptide repertoire for presentation to local 
immune cells. This can result in further attenuation of 
cytokine and receptor expression, which leads to an 
ineffective overall immune response and progression 
to carcinoma[33]. The Genome-Wide Association Study 
(GWAS) for polymorphisms of host immune response 
genes showed that variation in several genes contributes 
to different risks of cervical cancer. The integrative 
approach, which is also known as systems biology, could 
help explain the complexity of host–virus interactions 
and provide a better understanding that may eventually 
lead to personalized prevention, diagnosis, and treat-
ment[34-36]. 
The detection of methylated genes in cervical specmens 
is a feasible technique and represents a potential source 
of biomarkers that are of relevance to carcinogenesis. In 
particular, there are methylation markers that, among 
HPV-infected women, indicate the presence of CIN Ⅱ+ 
and risk of cancer[37].
High expression levels of certain oncoproteins in 
cervical cells have been found to be associated with 
cervical carcinoma. One study found a strong correlation 
between centromere protein H (CENP-H) expression and 
cervical carcinoma in a Chinese population[38]. Another 
study found that expression of the B-cell-specific Moloney 
leukemia virus insert site 1 (Bmi-1), P16, and CD44v6 
(a CD44 variant) were significantly higher in cervical 
carcinoma tissues compared with precancerous lesions 
and normal tissues[39]. In addition, abnormalities in the 
phosphatidylinositide 3-kinase (PI3K) pathway induced 
by mutations in PI3K catalytic subunit α (PIK3CA) 
were associated with shorter survival in cervical cancer 
patients[40]. Recently, deep sequencing of somatic 
mutations has identified several novel mutations in 
carcinoma cells, including E322K in the mitogen-
activated protein kinase 1 (MAPK1) gene, inactivating 
mutations in the major histocompatibility complex, class 
I, B (HLA-B) gene, and mutations in F-box and WD 
repeat domain containing 7 (FBXW7), tumor protein 
p53 (TP53), and Erb-B2 receptor tyrosine kinase 2 
(ERBB2)[41]. 
EPIGENETIC MECHANISMS AND RISK OF 
CANCER DEVELOPMENT
Recent studies also investigated epigenetic mechanisms 
related to HPV infection, including methylation of the 
host and viral genes, and chromatin modification 
in host cells[42]. Epigenetic mechanisms affect gene 
regulation without changing the genetic sequences, 
and these mechanisms have been increasingly found 
to be associated with cancer development[43]. The 
main epigenetic mechanism is methylation patterning, 
which occurs to various extents in different DNA and 
proteins. DNA methylation is a mechanism of gene 
regulation that typically occurs in CpG dinucleotide 
contexts, resulting in genomic instability. Methylation 
of heterochromatin and promoter regions is associated 
with decreased gene transcription. Several studies 
have found that DNA methylation frequently occurs 
in cervical cells but rarely in normal cells, suggesting 
that their methylation is highly related to the severity 
of cervical neoplasia[44]. Several markers have been 
evaluated extensively in studies involving women with 
precancerous and cancerous cervical lesions[44-46]. 
Epigenetic methylation in the promoter region of several 
tumor suppressor genes (TSGs) has been detected in 
precancerous cervical cells[47,48]. Genes that were found 
to be significantly associated with promoter methylation 
were RASSF1A and MGMT (involved in DNA repair), 
CDKN2A (involved in cell cycle control), PYCARD (involved 
in apoptosis), and APC and SFRP1 (involved in Wnt 
signaling)[49]. 
One striking conclusion of previous studies was 
that methylation frequencies for the same gene vary 
widely between studies. It was difficult to identify 
highly consistent results for most genes even when 
restricting analyses to studies of similar size or those 
that used common specimen sources or similar assays. 
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This suggests that the frequency of certain methylation 
markers may also vary for reasons related to differences 
in populations, specific features of assay protocols, 
chance, or other unidentified factors. The most impor-
tant prerequisite for a potential biomarker is that it must 
be reliable in its measurement. There is a possibility 
that the wide range of frequencies reported for some 
genes (in contrast to the more consistent measurement 
of a few other genes in similar studies) could be related 
to unreliable assays for these specific genes rather 
than biological variation. Another prerequisite for a 
good biomarker is that it has high sensitivity and high 
specificity for disease detection, resulting in a high 
positive predictive value. Several studies have proposed 
the use of methylated gene panels in order to obtain 
optimal assessment performance for cervical cancer 
screening[47,50].
Retinoic acid (RA) is an essential regulator of normal 
epithelial cell differentiation. The effect of RA is mediated 
by two types of nuclear receptors, the retinoic-acid 
receptor (RAR) family and retinoid-X receptor (RXR) 
family. Both of these receptor families have three 
members (alpha, beta, and gamma), which are encoded 
by distinct genes in vertebrates. The retinoic acid 
receptor beta (RARβ) gene encodes a nuclear receptor 
that binds RA and mediates cellular signaling. It is 
important during differentiation of stratified squamous 
epithelium, including cervical epithelium. It is considered 
to be a potential TSG. The RARβ  gene is usually ex-
pressed in normal epithelial tissue. The direct roles of 
the RARβ protein include regulating gene expression 
and differentiation, immune modulation, and inducing 
apoptosis. Previous studies revealed that the RARβ gene 
is downregulated in high-grade lesions[51]. RARβ gene 
silencing was observed in carcinoma cells[52]. Recent 
research suggested that the RARβ protein can suppress 
cervical carcinogenesis and may play a role in the early 
development of cancer[51]. CpG methylation of the 5’ 
region of the RARβ gene contributes to gene silencing, 
and this methylation is associated with increased 
grades of SIL and invasive cervical cancer. Many studies 
have revealed that methylation of CpG islands in the 
promoter region of the RARβ gene induces repression 
of RARβ  expression in several epithelial carcinomas, 
including cervical cancer[53-55]. 
The risk of cervical cancer due to RARβ methylation 
remains inconsistent across different studies[51,52,56]. 
Therefore, we reviewed previously published articles and 
summarized the relationship between RARβ promoter 
methylation and cervical cancer (Table 1).
Among the 14 articles reviewed, the majority of 
them (11/14) demonstrated that the frequency of RARβ 
promoter methylation was significantly correlated with 
severity of cervical epithelium abnormalities. Three 
studies did not concur with this finding. The first study 
was conducted in 2003 with a small sample size and no 
cancer patients were involved[37]. The other two studies 
were conducted in 2010 and 2015. Both studies found 
that normal tissue also had RARβ promoter methylation, 
which made it a poor predictor of progression to severe 
disease[62,64]. However, one of the two studies also 
investigated the level of methylation using quantitative 
methylation-specific PCR and found that although 
normal cells were methylated, the level of methylation 
increased in LSIL, HSIL, and invasive cancer tissue[62]. 
In addition, both Narayan et al[56] and Choi et al[60] 
found that RARβ promoter methylation was associated 
with cervical cancer prognosis. Narayan et al[56] found 
that 80% of the patients with RARβ methylation either 
died of cancer or only partly responded to treatment, 
while Choi et al[60] found that absence or reduction of 
RARβ protein expression was associated with a higher 
level of SCC antigen (P = 0.04) and more frequent 
lymph node metastasis (P = 0.023).
A study of the frequency of RARβ promoter methylation 
in urine and cervical samples from Senegalese women and 
cervical epithelial cell abnormalities found that methylation 
was significantly greater in abnormal specimens (and 
the results from the urine samples correlated with the 
results from the cervical swab samples)[58,65]. Another 
study by Zhang et al[52] compared the frequency of 
methylation with RARβ mRNA expression. The authors 
found that in normal cervical cells, the RARβ  gene 
was highly expressed. In contrast, among 17 samples 
from patients with invasive cervical carcinoma, RARβ2 
expression was completely repressed in 13 samples, 
highly repressed in 2 samples, and moderately down-
regulated in 2 samples. Among the 13 samples with 
completely repressed RARβ2 expression, the RARβ 
promoter region was methylated in 9 samples and 
unmethylated in 4 samples. The authors then further 
investigated the silencing mechanism and discovered 
that apart from methylation, repressive histone modifica-
tions also played a role in gene silencing, which could 
contribute to the development of cervical carcinoma.
Four studies performed a quantitative assessment of 
methylation. The first study was conducted in 2006 by 
Wisman et al[59], who found that the RARβ2 promoter 
was more methylated in cervical cancer than in control 
tissue. Four years later, Kim et al[61] found that the 
RARβ methylation level in normal tissue was 1.59% ± 
3.51% whereas, in HSIL and SCC, it was 21.93% ± 
20.10% and 19.06% ± 19.39%, respectively. The third 
study, by Yang et al[62], also highlighted that although 
the percentage of methylated samples was very high 
in normal tissue, the level of methylation correlated 
with disease severity. The last study was conducted 
by Sun et al[51] in 2015. They found that among 250 
cervical samples from healthy individuals and patients 
with various stages of cervical epithelium abnormalities, 
the percentage of methylation in patients showed that 
68.8% had no RARβ  promoter methylation, 26.4% 
had 0%-5% methylation, and 4.8% had 5%-25% 
methylation. No samples had methylation levels above 
25%.
In addition, two studies performed immunohisto-
chemistry staining of the RARβ protein in cervical cells. 
Narayan et al[56] found that in the LSIL group, 11% had 
Wongwarangkana C et al . RARβ  promoter methylation in cervical cancer
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Table 1  The summary of the articles that investigated the methylation of RARβ  gene in tumor tissue from women diagnosed with 
squamous intraepithelial lesion and cervical cancer
Ref. Year of Nationality of Sample size Source of samples Lab technique RARβ  methylation results
publication participants
Virmani et al[57] 200 American Normal/LSIL = 37 Normal/LSIL/HSIL from 
liquid-based cytology 
specimen
MSP RARβ  methylation positive in
HSIL = 7 ICC from biopsy tissue Normal/LSIL = % HSIL = 29%
ICC = 9 ICC = 26%
Narayan et al[56] 2003 Colombians Normal = 8 Normal = cells from 
cervical swab LSIL/HSIL 
= formalin-fixed and 
paraffin-embedded
MSP RARβ  methylation positive in
German LSIL = 9 cervical tissues Normal = 0% SCC/AC = 29.3%
American HSIL = 30 SCC/AC = tumor biopsies Immuno-
histochemistry 
of RARβ  protein
Immunohistochemistry
SCC = 77 LSIL; 11% showed low expression
AC = 5 HSIL; 60% showed complete lack of 
expression 
Gustafson et al[37] 2004 American Normal =  Liquid-based cytology 
specimen
Nested MSP RARβ  methylation positive in
LSIL = 7 Normal = 0% LSIL = 0% 
HSIL =  HSIL = 9.%
Feng et al[58] 2005 Senegalese Normal/ASCUS = 
42
Exfoliated cervical cells 
and tissue biopsy
MSP RARβ  methylation positive in
CIN Ⅰ = 39 Normal/ASCUS = 3.2%
CIN Ⅱ = 23 CIN Ⅰ = 0%
CIN Ⅲ = 23 CIN Ⅱ = 0%
ICC = 92 CIN Ⅲ = 5.8% ICC = 38.2%
Wisman et al[59] 2006 Dutch Normal = 9 Cervical scraping QMSP The percentage of RARβ  methylation 
level above control ratio were detected 
in Normal = 0% SCC = 5% AC = 25%
SCC = 20
AC = 8
Choi et al[60] 2007 Korean Normal = 37 Normal cells were from 
hysterectomy due to 
myoma
MSP RARβ  methylation positive in
SCC = 37 Cancer cells were from 
tissue after surgery
Immuno-
histochemistry 
of RARβ  protein
Normal = 0% SCC = 4%
Immunostaining normal = strong 
staining 
SCC = 43% absent staining
Zhang et al[52] 2007 Japanese and 
Chinese
Normal = 6 Cervical tissue by biopsy 
or surgery
Real-time PCR 
for RARβ  mRNA
RARβ  expression level among normal 
cells: All were highly expressed
ICC = 7 RARb2 expression level among cancer 
cells:
Semi-nested 
MSP
3/7: Completely repressed
2/7: Highly repressed
2/7: Moderately down-regulated
Among 3 samples with completely 
repressed mRNA expression
9 promoter methylated, 4 unmethylated
Flatley et al[2] 2009 English Normal = 58 Exfoliated cervical cells 
and cervical biopsy
Nested MSP RARβ  methylation positive in
CIN Ⅰ = 68 Normal = 6.5%
CIN Ⅱ = 56 CIN Ⅰ = 42.6%
CIN Ⅲ = 76 CIN Ⅱ = 6.3%
ICC = 50 CIN III = 0% ICC = 5.9%
Kim et al[54] 200 Korean Normal = 4 Liquid based cytology 
specimen
Multiplex nested 
MSP
RARβ  methylation positive in
LSIL = 32 Normal = 4.9% LSIL = 5.6%
HSIL = 67 SCC = 
69
HSIL = 46.3% SCC = 53.6%
Kim et al[6] 200 Korean Normal = 28 Liquid based cytology 
specimen
Multiplex QMSP RARβ  methylation level
Wongwarangkana C et al . RARβ  promoter methylation in cervical cancer
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low RARβ expression whereas, in the HSIL group, 60% 
had a complete lack of RARβ expression. This finding 
suggested that the downregulation of the RARβ gene 
occurs early in the development of cervical carcinoma[56]. 
The second study was carried out by Choi et al[60], who 
discovered that all normal tissues highly expressed the 
RARβ protein, whereas no staining was detected in 43% 
of the SCC tissues.
Almost of cancer cell lines and primary cancer tissues 
examined, the RARβ2 was repressed. The repression was 
frequently associated with promoter methylation, which 
causes lack of gene expression. These results strongly 
support the hypothesis that promoter methylation is 
the epigenetic cause of RARβ2 repression in cervical 
cancers harboring methylated RARβ2 promoters. A DNA 
demethylating reagent can reactivate gene expression 
by inducing drastic demethylation of the promoter in 
repressed cells carrying a methylated promoter[44]. This 
consistency between promoter demethylation and RARβ2 
derepression strongly suggests that the primary cause 
of RARβ2 repression is indeed promoter methylation. 
Several hypotheses have been proposed regarding 
the mechanisms of DNA methylation that lead to 
silencing of genes. In some cancer cells and tissues 
examined, RARβ2 was repressed without promoter 
methylation. These facts indicate that although DNA 
methylation is the major epigenetic mechanism for gene 
silencing, there are other epigenetic silencing pathways 
independent of DNA methylation. RARβ2 is frequently 
silenced in cervical cancers by one of two epigenetic 
mechanisms. One is DNA methylation, a well-known 
epigenetic mechanism leading to transcriptional silencing 
of genes, while the other involves the formation of 
repressive histone modifications near the promoter, by 
unknown mechanisms independent of DNA methylation. 
At present, the initial causes of these epigenetic changes 
during carcinogenesis are unclear. RARβ2 silenced by 
promoter methylation can be reactivated by promoter 
hypomethylation. This result indicates the importance 
of examining promoter methylation if epigenetic modula-
tion drugs are to be used for chemotherapy in patients 
with cervical cancers.
In conclusion, DNA methylation of TSGs likely 
contributes to the development of cancer. Although DNA 
LSIL = 26 Normal = .59+3.5% LSIL = 
3.67+9.09%
HSIL = 45 SCC = 
63
HSIL = 2.93+20.0% SCC = 
9.06+9.39%
Yang et al[62] 200 Dutch Normal = 20 Biopsy tissue QMSP RARβ  methylation positive (from 
tissue) in
LSIL = 20 Normal = 85% LSIL = 65%
HSIL = 20 Cervical scraping only 
available in subset of 
samples
HSIL = 75% SCC = 85% AC = 85%
SCC = 40 RARβ  methylation positive (from 
scraping) in
AC = 20 Normal = 44% LSIL = 37.5%
HSIL = 55.6% SCC = 83.8% AC = 00%
The median methylation level increased 
significantly with the severity of lesion 
(P < 0.05)
Pathak et al[63] 202 Indian Normal = 35 Normal cells from 
hysterectomy SIL from 
excision ICC from tissue 
biopsy
MSP RARβ  methylation positive in
SIL = 27 Normal = .4% SIL = 55.5% ICC = 
57.8%
ICC = 38
Milutin Gašperov et al[64] 205 Croatian Normal = 40 Cervical scraping MSP RARβ  methylation positive in
CIN Ⅰ = 40 Normal = 62.5%
CIN Ⅱ = 40 CIN Ⅰ = 35%
CIN Ⅲ = 42    CIN Ⅱ = 6.5%
SCC = 8 AC = 3 CIN Ⅲ = 6.9% SCC/AC = 90% 
Sun et al[5] 205 Chinese Normal = 48 Liquid based cytology 
specimen
Methylation 
specific high 
resolution 
melting analysis 
(Quantitative)
RARβ  methylation positive in
CIN Ⅰ = 54 Normal = 3.3% CIN Ⅰ = 35.2%
CIN Ⅱ = 47 CIN Ⅱ and Ⅲ = 28.2% SCC = 33.3%
CIN Ⅲ = 56 RARβ  methylation level: none = 68.8% 
SCC = 45 0-5% methylation = 26.4% 5-25% = 4.8%
CIN: Cervical intraepithelial neoplasia; SIL: Squamous intraepithelial lesion; LSIL: Low-grade squamous intraepithelial lesion; HSIL: High-grade squamous 
intraepithelial lesion; SCC: Squamous cell carcinoma of the cervix; AC: Adenocarcinoma of cervix; ICC: Invasive cervical cancer; MSP: Methylation-Specific 
Polymerase Chain Reaction; QMSP: Quantitative methylation-specific polymerase chain reaction; ASCUS: Atypical squamous cells of undetermined.
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methylation of only one gene may not represent the 
complete process of epigenetic silencing, it has been 
shown to be significantly correlated with cervical 
cancer. Analyzing combinations of aberrant hyper- or 
hypo-methylation of multiple genes may increase the 
sensitivity of prognoses. Thus, this approach may serve 
as a better tool for predicting disease progression. Risk 
factors should also be further characterized to better 
understand the pathogenesis of cervical carcinoma.
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